Roderick MacLeod Brings 20+ Years of Public and Private MedTech Organization Leadership Experience
West Lafayette, IN – August 12, 2025 – On the heels of celebrating the 1,000th patient using CYTALUX® (pafolacianine) and amidst a major expansion phase, On Target Laboratories is pleased to name Roderick (Rod) MacLeod as its new Chief Financial Officer. Mr. MacLeod has more than 20 years of experience leading finance for major medical technology organizations, both publicly traded and private, and will report to Chief Executive Officer, Bill Peters.
Mr. MacLeod joins On Target Laboratories from Nevro (NYSE: NVRO) where he was responsible for all aspects of financial planning, accounting, investor relations, sales operations and information technology for the leading high-frequency spinal cord stimulation technology company. While at Nevro, Mr. MacLeod drove significant changes in working capital management, pricing strategy and forecasting of all aspects of the business. Previously, he spent 16 years at Stryker Endoscopy where as Vice President of Finance (2011-2020) he played a key role in growing the business from $500 million in 2004 to $1.8 billion in 2020.
“I’ve respected and appreciated Rod’s impact on organizations for many years. He is not only an elite financial talent but someone who cares deeply about helping patients and surgeons battle cancer. We are honored he chose to join the On Target team and his deep expertise leading medical companies of all sizes will play a critical role in the huge commercial growth trajectory our company has successfully commenced,” said Bill Peters, chief executive officer, On Target Laboratories.
“On Target Laboratories is one of the most exciting and promising companies in the cancer innovation sphere and I couldn’t be more thrilled to join this brilliant and driven team,” said Rod MacLeod, chief financial officer, On Target Laboratories. “Having been deeply involved in the growth of leading medical technology organizations for more than 20 years, I see many similarities and opportunities here. I look forward to using my expertise in capital allocation, commercial execution, strategic planning and more to help ensure our innovations get into the hands of more and more surgeons across the country as quickly as possible.”
Mr. MacLeod holds a master of management from J.L. Kellogg Graduate School of Management at Northwestern University and a bachelor of arts in economics from Harvard University.
About On Target Laboratories, Inc.
On Target Laboratories discovers and develops targeted intraoperative molecular imaging agents to illuminate cancer during surgery. Their molecular imaging technology, based on the pioneering work of Philip S. Low, PhD, Purdue University’s Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry, is comprised of a near-infrared dye and a targeting molecule, or ligand, that binds to receptors overexpressed on cancer cells. The imaging agents illuminate the cancerous tissue, which may enable surgeons to detect more cancer that otherwise may have been left behind.
CYTALUX, the Company’s first product, received FDA approval of a New Drug Application for ovarian cancer in November 2021 and a supplemental New Drug Application for lung cancer in December 2022. CYTALUX targets the folate receptors commonly found on many cancers, binds to the cancerous tissue, and illuminates under near-infrared light. A single dose of the agent is administered via intravenous infusion prior to surgery and assists surgeons in visually identifying additional cancerous tissue to be removed during the operation. For more information and to view full Prescribing Information visit www.ontargetlabs.com and www.cytalux.com.